Sarep­ta li­cens­es next-gen AAV tech from Broad In­sti­tute in deal cov­er­ing five in­di­ca­tions — in­clud­ing Duchenne

Sarep­ta’s re­search agree­ment with the Broad In­sti­tute is tak­ing the next step Mon­day.

The biotech will li­cense a new group of ade­no-as­so­ci­at­ed virus­es from the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER